← Leaderboards
Janet Lo
Massachusetts General Hospital
$8,224,042
Attributed
$12,257,167
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,257,167 · 6
By mechanism
R01$11,127,913 · 3
K23$704,888 · 1
K24$412,458 · 1
F32$11,908 · 1
Top collaborators
- Ahmed A Tawakol5 shared
- Michael Ilya Bukrinsky4 shared
- Michael Leo Fitzgerald4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- Michael Leo Fitzgerald$6,905,590
- Udo Hoffmann$17,171,978
- Ahmed A Tawakol$9,912,063
- Filip K Swirski$20,484,870
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Daniel James Rader · University Of Pennsylvania$50,278,074
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
Research focus
AtherosclerosisInflammationHiv InfectionsRandomizedInflammatoryMonocyteMetabolicResearch PersonnelCardiovascular DiseasesCardiovascular Disorder RiskPlacebosLeadX-Ray Computed TomographyCardiovascular Risk FactorPlacebo ControlCellsBiologicalPrevention StrategyCoronary ArteriosclerosisInsulin ResistanceArterial Fatty StreakMacrophageDyslipidemiasPatient Population
Grant awards (22)
Effects of Targeting Immune Activation and Intestinal Barrier on Comorbidities in People with HIV$206,175
K24 · FY2025 · AI · contact PI
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$744,797
R01 · FY2024 · HL · contact PI
Effects of Targeting Immune Activation and Intestinal Barrier on Comorbidities in People with HIV$206,283
K24 · FY2024 · AI · contact PI
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$750,673
R01 · FY2023 · HL · contact PI
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$771,996
R01 · FY2022 · HL · contact PI
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$778,106
R01 · FY2021 · HL · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$777,389
R01 · FY2021 · HL
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$829,709
R01 · FY2020 · HL · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$784,578
R01 · FY2020 · HL
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$793,579
R01 · FY2019 · HL
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV$827,188
R01 · FY2018 · HL · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$787,681
R01 · FY2018 · HL
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV$822,455
R01 · FY2017 · HL · contact PI
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV$822,455
R01 · FY2016 · HL · contact PI
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV$810,119
R01 · FY2015 · HL · contact PI
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV$827,188
R01 · FY2014 · HL · contact PI
Atherosclerosis and Inflammation in HIV Disease$141,750
K23 · FY2012 · HL · contact PI
Atherosclerosis and Inflammation in HIV Disease$141,750
K23 · FY2011 · HL · contact PI
Atherosclerosis and Inflammation in HIV Disease$141,561
K23 · FY2010 · HL · contact PI
Atherosclerosis and Inflammation in HIV Disease$139,913
K23 · FY2009 · HL · contact PI
Atherosclerosis and Inflammation in HIV Disease$139,914
K23 · FY2008 · HL · contact PI
Subclinical Coronary Atherosclerosis in HIV-Infected Patients$11,908
F32 · FY2007 · HL · contact PI